CN100404073C - 一种难溶性药物凝胶制剂制备方法 - Google Patents
一种难溶性药物凝胶制剂制备方法 Download PDFInfo
- Publication number
- CN100404073C CN100404073C CNB2004100307478A CN200410030747A CN100404073C CN 100404073 C CN100404073 C CN 100404073C CN B2004100307478 A CNB2004100307478 A CN B2004100307478A CN 200410030747 A CN200410030747 A CN 200410030747A CN 100404073 C CN100404073 C CN 100404073C
- Authority
- CN
- China
- Prior art keywords
- gel
- preparation
- carbomer
- adds
- poloxamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 title description 7
- 238000009472 formulation Methods 0.000 title description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 229960003276 erythromycin Drugs 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229940082484 carbomer-934 Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229940044519 poloxamer 188 Drugs 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 4
- 229960004063 propylene glycol Drugs 0.000 claims description 4
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 29
- 239000000126 substance Substances 0.000 abstract description 10
- 239000013543 active substance Substances 0.000 abstract description 6
- 230000003165 hydrotropic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 24
- 239000000499 gel Substances 0.000 description 22
- 239000000758 substrate Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 229940073647 emgel Drugs 0.000 description 5
- 229960004125 ketoconazole Drugs 0.000 description 5
- 229940097572 chloromycetin Drugs 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
- 229960004099 azithromycin Drugs 0.000 description 3
- 229960002206 bifonazole Drugs 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100307478A CN100404073C (zh) | 2004-04-02 | 2004-04-02 | 一种难溶性药物凝胶制剂制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100307478A CN100404073C (zh) | 2004-04-02 | 2004-04-02 | 一种难溶性药物凝胶制剂制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1676120A CN1676120A (zh) | 2005-10-05 |
CN100404073C true CN100404073C (zh) | 2008-07-23 |
Family
ID=35048971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100307478A Expired - Lifetime CN100404073C (zh) | 2004-04-02 | 2004-04-02 | 一种难溶性药物凝胶制剂制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100404073C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525885B (zh) * | 2011-11-21 | 2017-06-27 | 程雪翔 | 一种酮康唑凝胶及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1397272A (zh) * | 2002-08-19 | 2003-02-19 | 上海兴康医药研究开发有限公司 | 可滴眼用在体凝胶制剂及其制备方法 |
-
2004
- 2004-04-02 CN CNB2004100307478A patent/CN100404073C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1397272A (zh) * | 2002-08-19 | 2003-02-19 | 上海兴康医药研究开发有限公司 | 可滴眼用在体凝胶制剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
酮康唑凝胶剂的制备及临床疗效观察. 范义凤,王华.制剂技术,第12卷第4期. 2003 |
酮康唑凝胶剂的制备及临床疗效观察. 范义凤,王华.制剂技术,第12卷第4期. 2003 * |
阿奇霉素凝胶的制备及质量控制. 张国友,宣艳.中国药师,第6卷第4期. 2003 |
阿奇霉素凝胶的制备及质量控制. 张国友,宣艳.中国药师,第6卷第4期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1676120A (zh) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1407898A (zh) | 具有全身效应的新型局部雌激素孕激素组合物 | |
CZ20003471A3 (cs) | Lokální hormonální prostředek se systémovým účinkem | |
CN1133565A (zh) | 经鼻吸收的组合物以及含有该组合物的经鼻吸收制剂 | |
CN101675918A (zh) | 一种自乳化微乳组合物及其制备方法和用途 | |
CN100341577C (zh) | 经皮吸收制剂 | |
CN1989956B (zh) | 一种阿达帕林凝胶组合物及其制备方法 | |
CN100375621C (zh) | 长春瑞滨脂质微球注射液及其制备方法 | |
CN101862294B (zh) | 一种伊维菌素的悬乳剂及其制备方法和应用 | |
CN101524329B (zh) | 双环醇亚微乳及其制备方法 | |
CN102772363B (zh) | 一种含泊那珠利的溶液剂及其制备方法 | |
CN108926534A (zh) | Kgm改性卵磷脂载nmn透皮醇质体、制剂及其制备工艺与应用 | |
CN101991532B (zh) | 一种自微乳组合物、一种微乳,及它们的制备方法 | |
CN101631534A (zh) | 用于跨膜给药对乙酰氨基酚的盖仑制剂 | |
CN101422431B (zh) | 胰岛素经鼻给药制剂 | |
CN101181227B (zh) | 生物黏附性环孢素a固体脂质纳米粒原位凝胶制剂及其制备方法 | |
CN101181638A (zh) | 女性表面涂敷用避孕剂 | |
CN101147727A (zh) | 莪术醇亚微乳及其制备方法和制剂 | |
CN100998592A (zh) | 苦参碱微乳 | |
CN100404073C (zh) | 一种难溶性药物凝胶制剂制备方法 | |
CN101623255B (zh) | 一种青蒿琥酯纳米乳药物组合物及其制备方法 | |
CN102552137A (zh) | 雷公藤内酯醇脂肪乳注射剂及其制备方法 | |
CN102058545B (zh) | 一种注射用美罗培南冻干制剂及其制备方法 | |
CN110251487A (zh) | 一种提高多西他赛载药量和口服生物利用度的醇溶蛋白纳米粒的制备方法及其应用 | |
CN1739519B (zh) | 伊曲康唑注射乳剂及其制备方法 | |
CN107998072A (zh) | 克霉唑乳膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20120611 Granted publication date: 20080723 |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20121211 Granted publication date: 20080723 |
|
PP01 | Preservation of patent right |
Effective date of registration: 20121211 Granted publication date: 20080723 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20130611 Granted publication date: 20080723 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PP01 | Preservation of patent right |
Effective date of registration: 20140530 Granted publication date: 20080723 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20150530 Granted publication date: 20080723 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201126 Address after: No. 279 Nanhai Road, Xiuying District 570314 Hainan city of Haikou Province Patentee after: AVENTIS PHARMA (HAINAN) Co.,Ltd. Address before: 100089, Wanquan mansion, three Jin Zhuang, Haidian District, Beijing, Sijiqing Patentee before: BEIJING VENTUREPHARM TECHNOLOGY Corp. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Song Xuemei Document name: Notice of conformity |
|
CX01 | Expiry of patent term |
Granted publication date: 20080723 |
|
CX01 | Expiry of patent term |